Topics:

Ovarian Cancer

Maintenance Pazopanib in Ovarian Cancer: No Survival Benefit, High AEs

Maintenance therapy with pazopanib improved progression-free survival by 5.6 months in advanced ovarian cancer patients, according to results of a new study

Ovarian Cancer

Researchers have used observational study data to better define risks for breast and ovarian cancers associated with mutations in the BRCA1 or BRCA2 genes.

The use of intraperitoneal chemotherapy for the treatment of advanced ovarian cancer resulted in a survival benefit over intravenous chemotherapy.

Onset of alopecia within the first 3 cycles of chemotherapy was associated with improved survival in ovarian cancer patients who completed 6 cycles of chemo.

Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity.

A large meta-analysis found that women who were users of hormone therapy, even those with less than 5 years of use, had an increased risk of ovarian cancer.

The US Food and Drug Administration has granted Orphan Drug Designation to pelareorep (Reolysin) for the treatment of ovarian cancer.

Despite achieving complete surgical resection, advanced epithelial ovarian cancer or primary peritoneal cancer patients with a high disease burden had worse survival outcomes than those with lower disease burden.

Pages

Subscribe to Ovarian Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.